Effect of Acute Limb Ischemia on the Mortality of Patients with Extracorporeal Membrane Oxygenation Established by Femoral Vein-Arterial Catheterization and Analysis of Related Risk Factors

Xiang Li,1 Guang Chen,1 Sheng Zhang,2 Xinting Zheng,3 Wenjun Zhao,1 and Dun Hong4

1Department of Vascular Surgery, Taizhou Hospital Affiliated to Wenzhou Medical University (Zhejiang Province Taizhou Hospital), Taizhou 317000, Zhejiang, China
2Department of ICU, Taizhou Hospital Affiliated to Wenzhou Medical University (Zhejiang Province Taizhou Hospital), Taizhou 317000, Zhejiang, China
3Department of General Practice, Taizhou Hospital Affiliated to Wenzhou Medical University (Zhejiang Province Taizhou Hospital), Taizhou 317000, Zhejiang, China
4Department of Orthopaedics, Taizhou Hospital Affiliated to Wenzhou Medical University (Zhejiang Province Taizhou Hospital), Taizhou 317000, Zhejiang, China

Correspondence should be addressed to Dun Hong; 397501828@163.com

Received 2 August 2021; Accepted 17 August 2021; Published 31 August 2021

Academic Editor: Songwen Tan

Extracorporeal membrane oxygenation (ECMO) is a common treatment for cardiopulmonary failure. Although it can effectively reduce the mortality of patients with cardiopulmonary failure, it still has a high mortality rate, such as acute limb ischemia (ALI), stroke, liver and kidney failure, and other related complications and related causes of death. This study aims to explore the impact of ALI on the mortality of VA-ECMO patients in hospital and 6 months after discharge and analyze the occurrence of ALI and related factors that affect the mortality of VA-ECMO in hospital and 6 months after discharge. The results showed that the smoking history was an independent risk factor for ALI, and age, diabetes, cardiac arrest, first time of ECMO, and hyperbilirubinemia were associated risk factors for in-hospital mortality. Cardiac arrest and ALI were associated risk factors for mortality at 6 months after discharge. Although ALI is not significantly associated with VA-ECMO in-hospital mortality, it is a risk factor for mortality at 6 months after discharge, and medical personnel should therefore strive to reduce and avoid ALI.

1. Introduction

Extracorporeal membrane oxygenation (ECMO) is a continuous extracorporeal vital sign treatment method, which uses extracorporeal equipment to replace or partially replace the human heart and lung functions, and supports life to fight for the chance of heart and lung disease healing and functional recovery [1, 2]. The two main configurations of ECMO currently in use are vein-venous (V-V) ECMO for respiratory support and vein-arterial (V-A) ECMO for cardiopulmonary support. For patients with cardiopulmonary insufficiency, V-A ECMO is the first choice of supportive treatment, which can provide comprehensive cardiopulmonary support. ECMO as a treatment for cardiopulmonary failure has grown exponentially over the past decade, and several landmark studies have shown that ECMO is effective in reducing mortality in cardiopulmonary failure [3, 4]. However, ECMO itself is not without major complications, and it still has a high mortality rate, such as acute limb ischemia (ALI), stroke, and liver and kidney failure, which are related complications and causes of death [5–8]. ALI is a common emergency in vascular surgery. If it is not treated in time, it can cause irreversible necrosis of the limbs and amputation and even endanger the life of the
patient [9]. Therefore, it is extremely important to explore the risk factors of ALI in patients and prevent them. Although the ECMO patients survival has improved significantly, what factors affect mortality is still not clear, and there is still lack of relevant data and research on the impact of vascular complications on the prognosis of VA-ECMO patients, especially in the ischemic vascular complications of hospital mortality and six months after hospital discharge, mortality, and the influence of other complications [10–12]. This study aims to explore the impact of ALI on the mortality of VA-ECMO patients in hospital and 6 months after discharge and analyze the occurrence of ALI and related factors that affect the mortality of VA-ECMO in hospital and 6 months after discharge. The specific report is as follows.

2. Materials and Methods

2.1. Patients. A retrospective analysis of the clinical data of 124 VA-ECMO patients admitted to the ICU in our hospital from August 2017 to August 2020. Inclusion criteria: all received VA-ECMO treatment; survived more than two hours after VA-ECMO was initiated (regardless of whether there is cardiogenic shock or respiratory failure); clinical data are complete. Exclusion criteria: there are contraindications for ECMO supportive treatment; those with congenital heart disease; those with un repaired aortic dissection; those with severe valve insufficiency; those who fall off during follow-up. This study was approved by the ethics committee of our hospital, and informed consent was signed by the patients and their families.

2.2. ECMO Support the Treatment Intubation Method. The specific intubation method of ECMO is the same as previous research reports [13]. The appropriate type of cannula was selected according to the height and weight of the patients, and single lumen cannula was used for venous and arterial catheterization. The right femoral artery is preferred for femoral artery intubation, and the left femoral artery intubation is used if the right femoral artery is used for other treatments or if ultrasound suggests other obstacles to intubation.

2.3. Research Method. Ischemic vascular complications were defined as ALI [14] with changes in lower limb symptoms (decreased skin temperature and loss of arterial pulsation) and loss of peripheral Doppler flow signals (vascular anastomotic repair during ECMO extubation was not included in the scope of vascular complications). Intervention options for ischemic vascular complications include open thrombolysis, intravascular interventional repair, fasciotomy decompression, or amputation. The ECMO team in our hospital is composed of doctors from ICU and vascular surgery. The femoral arteriovenous cannula is percutaneously punctured and cannulated by the vascular surgery assisting ICU doctor under the guidance of B-ultrasound. The process is managed by the ICU throughout the process, and the extubation is sutured by the ICU doctor assisting the vascular surgeon using the ProGlide suture device. If acute vascular complications occur during the period, the vascular surgeon is the mainstay, and the orthopedics and cardiothoracic surgery departments will assist in the rescue.

All patients were divided into the limb ischemia group and nonlimb ischemia group according to the presence or absence of ALI. The in-hospital mortality and the mortality 6 months after discharge were recorded and compared between the two groups. Age, sex, chronic medical history, ECMO intubation (catheterization method, type and location of the drainage tube and perfusion tube, and distal perfusion tube DPC), and other clinical data of all patients were recorded. The hospitalized death/survival status of the patients was recorded. The hospitalized surviving patients were followed up from the first day after discharge, and all were followed up for 6 months. The death/survival status was recorded through outpatient follow-up, telephone, or on-site follow-up.

2.4. Statistical Method. The results of this experiment were statistically analyzed by SPSS 20.0 (SPSS Co., Ltd., Chicago, USA). Normally distributed measurement data are represented by (mean ± standard deviation), and the t-test was used for their comparison between groups. Nonnormally distributed measurement data are represented by the median (25th percentile, 75th percentile) (M (P25, P75)), and the Mann–Whitney U test is used for analysis. Count data were expressed by (rate), and the chi-square test was used for their comparison between groups. Multivariate analysis adopts the multiple logistic regression model. \( P < 0.05 \) indicates that the difference is statistically significant.

3. Results

3.1. Univariate Analysis of Influencing the Occurrence of ALI in Patients. A total of 124 patients were included in this study, including 16 patients with acute limb ischemia (7 patients with open thrombectomy, 1 patient with fasciotomy and decompression, and 8 patients with family members who chose conservative palliative care) and 108 patients without limb ischemia. Univariate analysis showed that the smoking history was associated with ALI \( (P < 0.05) \), as given in Table 1.

3.2. Multifactor Analysis of Influencing the Occurrence of ALI in Patients. Multivariate logistic analysis showed that age, proportion of female, BMI, hypertension, diabetes, cardiac arrest, drainage tube model, perfusion tube model, drainage-perfusion tube ipsilateral, distal perfusion tube DPC, first auxiliary time of ECMO, and hyperbilirubinemia had no significant correlation with the occurrence of ALI \( (P > 0.05) \). Smoking history was an independent factor of ALI \( (P < 0.05) \), as given in Tables 2 and 3.

3.3. Outcome of ECMO Patients with the Limb Ischemia Group and Nonlimb Ischemia Group. In the limb ischemia group, 6 patients died in hospital, 9 patients died within 6
3.4. Univariate Analysis of Influence on Death in ECMO Patients. Among the 124 ECMO patients, 56 died in hospital and 68 survived in hospital. According to the death/survival of the patients, they were divided into the hospitalized death group and hospitalized survival group for analysis. Univariate analysis showed that age, diabetes, cardiac arrest, ECMO first auxiliary time, and hyperbilirubinemia were related to hospital death of ECMO patients ($P < 0.05$), as given in Table 4.

3.5. Multivariate Analysis of Factors Affecting the Death of ECMO Patients in Hospital. Multivariate logistic analysis showed that age, diabetes, cardiac arrest, ECMO first assist time, and hyperbilirubinemia were independent influencing factors of hospital death in ECMO patients ($P < 0.05$), as given in Tables 5 and 6.

3.6. Univariate Analysis of Mortality of ECMO Patients 6 Months after Discharge. Among 68 ECMO patients, 35 died and 33 survived 6 months after discharge. According to the death/survival of patients, they were divided into 6-month discharged death group and 6-month discharged survival group for analysis. Univariate analysis showed that cardiac arrest and ALI were related to death of ECMO patients at 6 months after discharge ($P < 0.05$), as given in Table 7.

3.7. Multifactor Analysis of Mortality of ECMO Patients 6 Months after Discharge. Multivariate logistic analysis showed that cardiac arrest and ALI were independent factors
influencing the death of ECMO patients at 6 months after discharge ($P < 0.05$), as given in Tables 8 and 9.

### 4. Discussion

In the past few years, the use of ECMO is more and more wide, and the use of ECMO in our hospital is also increasing year by year. However, ECMO is not without risks. Many factors are affecting the prognosis of patients with ECMO. The most important preoperative influencing factor for the prognosis of patients is the patient’s basic condition, which is often not obvious at the beginning of ECMO. Once ECMO is officially initiated, complications often determine the prognosis of patients with ECMO [15, 16]. Vascular and neurological complications are probably the most devastating because of their irreversible nature and their clear association with mortality [17–20]. At present, there are various reports on the incidence of VA-ECMO vascular complications in the literature. The association between vascular complications and mortality has not been fully established, some studies have not established the association between ALI and mortality, and there is a wide range of opinions about what factors affect mortality in ECMO patients. There is also a wide variety of literature with conflicting conclusions and no guideline conclusion or expert consensus [21–24].

There is literature that age, history of diabetes, history of stroke, and history of peripheral arterial disease are predisposing factors related to limb ischemia in ECMO patients [25]. However, in this study, the predisposing factor related

| Variables                              | $B$   | S.E  | Wald   | $P$   | OR   | 95% CI  |
|----------------------------------------|-------|------|--------|-------|------|---------|
| Age                                    | −0.023| 0.058| 1.843  | 0.235 | 0.977| 0.941–1.015|
| Proportion of female                   | −0.277| 0.304| 0.498  | 0.651 | 0.758| 0.227–2.524|
| BMI                                    | 0.124 | 0.105| 2.216  | 0.196 | 1.132| 0.938–1.365|
| Hypertension                           | 0.414 | 0.231| 0.815  | 0.471 | 1.513| 0.491–4.657|
| Diabetes                               | 0.639 | 0.547| 0.608  | 0.421 | 1.894| 0.401–8.938|
| Smoking history                        | 1.559 | 0.682| 7.538  | 0.005 | 4.752| 1.598–12.131|
| Cardiac arrest                         | 0.528 | 0.369| 1.249  | 0.263 | 1.281| 0.830–1.975|
| Drainage tube model                    | 0.358 | 0.593| 3.416  | 0.091 | 1.431| 0.946–2.162|
| Perfusion tube model                   | 0.248 | 0.169| 1.725  | 0.196 | 1.132| 0.938–1.365|
| Drainage-perfusion tube ipsilateral    | −0.362| 0.241| 0.649  | 0.302 | 0.507| 0.242–2.004|
| Distal perfusion tube DPC              | −0.141| 0.382| 0.205  | 0.696 | 0.869| 0.512–5.617|
| ECMO first auxiliary time              | 0.005 | 0.016| 3.412  | 0.092 | 1.005| 0.999–1.011|
| Hyperbilirubinemia                     | 0.549 | 0.398| 1.419  | 0.322 | 1.731| 0.587–5.094|

*Figure 1: Outcome of ECMO patients with the limb ischemia group and nonlimb ischemia group. Note: compared with the limb ischemia group, $P < 0.05$. 

Table 3: Multifactor analysis of influencing the occurrence of ALI in patients.
to limb ischemia was smoking history, and other related factors such as demographic characteristics, chronic disease history, and other complications were not significantly related to acute limb ischemia. Some literature believes that the lack of the distal perfusion tube (DPC) is a very important risk factor related to limb ischemia. A meta-analysis of 22 retrospective studies evaluating the impact of DPC on the risk of limb ischemia showed that although there was no statistically significant difference in mortality between the DPC and non-DPC cohorts, the DPC group reduced the incidence of absolute limb ischemia by 15.7% compared with the non-DPC group (9.74% vs. 25.42%) [26]. This study also wanted to verify the correlation between ECMO intubation and acute limb ischemia and mortality, which could be analyzed statistically from the existing data in our hospital.

The results showed that there was no significant correlation between ECMO catheterization (prechatheterization, percutaneous puncture, incision, and incision + puncture), size and length of the drainage tube and perfusion tube, placement position of two tubes, and DPC with ALI and mortality. There is a literature showing a higher mortality rate in patients with limb ischemia and a strong association between vascular complications and hospital mortality. In that literature cohort, the survival rate at discharge was 18% and 49% for patients with and without vascular complications by the multivariate analysis, with a hazard ratio of 2.17 \( (P = 0.02) \) [27]. However, the results of this study showed that limb ischemia had no direct effect on in-hospital mortality, but was significantly associated with mortality at 6 months after discharge.

| Table 4: Univariate analysis of influence on death in ECMO patients. |
|---------------------------------------------------------------|
| **Variables** | **n** | **The hospitalized death group (n = 56)** | **The hospitalized survival group (n = 68)** | **P** |
|----------------|-------|-------------------------------------------|-------------------------------------------|------|
| Age (year)     | 124   | 61.91 ± 16.80                             | 55.14 ± 9.45                              | 0.006|
| Proportion of female (%) | 37 | 18 (32.14) | 19 (27.94) | 0.611|
| BMI (kg/m²)    | 124   | 23.61 ± 2.15                              | 23.42 ± 2.93                              | 0.621|
| Hypertension   | 49    | 22 (39.29)                                | 27 (39.71)                                | 0.962|
| Diabetes       | 25    | 5 (8.93)                                  | 20 (29.41)                                | 0.005|
| Hyperlipidemia | 5     | 1 (1.79)                                  | 4 (5.88)                                  | 0.248|
| Long history of oral anticoagulants (%) | 10 | 3 (5.35) | 7 (10.29) | 0.315|
| History of myocardial infarction (%) | 9 | 6 (10.71) | 3 (4.41) | 0.178|
| Smoking history (%) | 32 | 11 (19.46) | 21 (30.88) | 0.155|
| History of COPD (%) | 1 | 0 (0.00) | 1 (1.47) | 0.362|
| History of chronic kidney disease (%) | 2 | 0 (0.00) | 2 (2.94) | 0.196|
| Cardiac arrest (%) | 81 | 44 (78.57) | 37 (54.41) | 0.005|
| Drainage tube model (F) | 124 | 21.00 (18.00, 24.00) | 20.00 (15.00, 24.00) | 0.322|
| Perfusion tube model (F) | 124 | 16.00 (14.00, 17.00) | 16.00 (15.00, 23.00) | 0.075|
| Drainage-perfusion tube ipsilateral (%) | 64 | 32 (57.14) | 32 (47.06) | 0.263|
| Distal perfusion tube DPC (%) | 43 | 18 (32.14) | 25 (36.76) | 0.591|
| ECMO first auxiliary time (h) | 124 | 37.50 (0.33, 296.20) | 106.80 (10.30, 405.90) | 0.001|
| Bleeding complications (%) | 13 | 5 (8.93) | 8 (11.76) | 0.608|
| Acute stroke (%) | 6 | 2 (3.57) | 4 (5.88) | 0.531|
| Hyperbilirubinemia (%) | 63 | 36 (64.29) | 27 (39.71) | 0.006|
| ALI (%) | 16 | 6 (10.71) | 10 (14.71) | 0.509|

| Table 5: Assignment for the multivariate analysis of factors. |
|---------------------------------------------------------------|
| **Factors** | **Variable** | **Assignment** |
|----------------|---------------|----------------|
| Age            | X1            | Continuous variable |
| Proportion of female | X2 | No = 0, Yes = 1 |
| BMI            | X3            | Continuous variable |
| Hypertension   | X4            | No = 0, Yes = 1 |
| Diabetes       | X5            | No = 0, Yes = 1 |
| Long history of oral anticoagulants | X6 | No = 0, Yes = 1 |
| History of myocardial infarction | X7 | No = 0, Yes = 1 |
| Smoking history | X8 | No = 0, Yes = 1 |
| Cardiac arrest | X9            | No = 0, Yes = 1 |
| Drainage tube model | X10 | Continuous variable |
| Perfusion tube model | X11 | Continuous variable |
| Drainage-perfusion tube ipsilateral | X12 | No = 0, Yes = 1 |
| Distal perfusion tube DPC | X13 | No = 0, Yes = 1 |
| ECMO first auxiliary time | X14 | Continuous variable |
| Acute stroke | X15           | No = 0, Yes = 1 |
| Hyperbilirubinemia | X16 | No = 0, Yes = 1 |
| ALI            | X17           | No = 0, Yes = 1 |
In this study, why is ALI a predictor of mortality at 6 months after discharge, but not of in-hospital death? In 16 patients with ALI, 8 of them were treated with open thrombectomy and fasciotomy and decompression, all of them survived and were discharged, 7 died 6 months after discharge, and 1 survived. 8 patients were treated conservatively, 6 died during hospitalization, and 2 died 6 months after discharge. Presumably, ALI was actually associated with in-hospital mortality, but the intervention of the vascular surgeon improved ALI and saved the patient’s life, so the effect on in-hospital mortality was statistically reduced. It can be concluded that ALI has an impact on in-hospital mortality, but further data and evidence are needed to support this. Although specific perspectives and conclusions vary from literature to literature, there is a common view that ischemic vascular complications have a significant impact on mortality and prognosis in ECMO patients, so we believe that prevention is critical. Early diagnosis of ECMO patients at risk of acute limb ischemia through clinical examination, Doppler ultrasound, ECG monitoring, and angiography, thus enabling patients to achieve better outcomes and has received increasing attention [28]. Once limb ischemia is detected, immediate action should be taken to reverse ischemic vascular complications.

Table 6: Multivariate analysis of factors affecting the death of ECMO patients in hospital.

| Variables                                       | B    | S.E  | Wald | P     | OR   | 95% CI          |
|------------------------------------------------|------|------|------|-------|------|-----------------|
| Age                                            | 0.041| 0.014| 6.895| 0.008 | 1.041| 1.011–1.071     |
| Proportion of female                           | -0.199 | 0.468 | 0.491 | 0.611 | 0.611 | 0.378–1.770     |
| BMI                                            | 0.034 | 0.106 | 0.504 | 0.618 | 1.035 | 0.904–1.185     |
| Hypertension                                   | 0.018 | 0.405 | 0.108 | 0.962 | 1.018 | 0.494–2.098     |
| Diabetes                                       | 1.447 | 1.263 | 6.941 | 0.007 | 1.018 | 1.011–1.071     |
| Long history of oral anticoagulants            | 0.707 | 0.954 | 0.765 | 0.323 | 2.027 | 0.499–8.235     |
| History of myocardial infarction               | 0.956 | 0.988 | 1.059 | 0.192 | 2.601 | 0.620–10.909    |
| Smoking history                                | 0.603 | 0.406 | 1.518 | 0.157 | 1.828 | 0.792–4.218     |
| Cardiac arrest                                 | 1.122 | 0.896 | 7.015 | 0.006 | 3.072 | 1.385–6.816     |
| Drainage tube model                            | 0.098 | 0.069 | 0.681 | 0.426 | 1.103 | 0.866–1.405     |
| Perfusion tube model                           | -0.399 | 0.145 | 3.026 | 0.096 | 0.671 | 0.420–1.073     |
| Drainage-perfusion tube ipsilateral           | -0.405 | 0.106 | 0.912 | 0.364 | 0.671 | 0.420–1.073     |
| Distal perfusion tube DPC                      | -0.205 | 0.219 | 0.591 | 0.264 | 0.591 | 0.368–1.719     |
| ECMO first auxiliary time                      | -0.009 | 0.003 | 7.369 | 0.001 | 0.991 | 0.985–0.997     |
| Acute stroke                                   | 0.523 | 1.168 | 2.667 | 0.444 | 1.568 | 0.687–3.619     |
| Hyperbilirubinemia                             | 0.036 | 0.015 | 1.828 | 0.178 | 1.736 | 1.082–2.788     |

Table 7: Univariate analysis of mortality of ECMO patients 6 months after discharge.

| Variables                                      | n   | The 6-month discharge death group (n = 35) | The 6-month discharge survival group (n = 33) | P   |
|------------------------------------------------|-----|--------------------------------------------|-----------------------------------------------|-----|
| Age (year)                                     | 68  | 65.10 ± 8.29                               | 53.71 ± 9.08                                  | 0.262|
| Proportion of female (%)                       | 19  | 8 (22.86)                                  | 11 (33.33)                                    | 0.336|
| BMI (kg/m²)                                    | 68  | 23.21 ± 3.06                               | 23.59 ± 2.78                                  | 0.498|
| Hypertension (%)                               | 27  | 14 (40.00)                                 | 13 (39.39)                                    | 0.959|
| Diabetes (%)                                   | 20  | 12 (34.29)                                 | 8 (24.24)                                     | 0.364|
| Hyperlipidemia (%)                             | 4   | 3 (8.57)                                   | 1 (3.03)                                      | 0.332|
| Long history of oral anticoagulants (%)        | 7   | 2 (5.71)                                   | 5 (15.15)                                     | 0.201|
| History of myocardial infarction (%)           | 3   | 1 (2.86)                                   | 2 (6.06)                                      | 0.521|
| Smoking history (%)                            | 21  | 13 (37.14)                                 | 8 (24.24)                                     | 0.249|
| History of COPD (%)                            | 1   | 0 (0.00)                                   | 1 (3.03)                                      | 0.299|
| History of chronic kidney disease (%)          | 2   | 0 (0.00)                                   | 1 (3.03)                                      | 0.966|
| Cardiac arrest (%)                             | 37  | 29 (82.86)                                 | 8 (24.24)                                     | 0.001|
| Drainage tube model (F)                        | 68  | 20.00 (15.00, 24.00)                       | 22.00 (18.00, 24.00)                          | 0.231|
| Perfusion tube model (F)                       | 68  | 16.00 (15.00, 23.00)                       | 16.00 (15.00, 18.00)                          | 0.495|
| Drainage-perfusion tube ipsilateral (%)        | 32  | 16 (45.71)                                 | 16 (48.48)                                    | 0.819|
| Distal perfusion tube DPC (%)                  | 25  | 10 (28.57)                                 | 15 (45.45)                                    | 0.149|
| ECMO first auxiliary time (h)                  | 68  | 106.80 (10.30, 218.60)                     | 106.30 (43.75, 405.90)                        | 0.129|
| Bleeding complications (%)                     | 8   | 4 (11.43)                                  | 4 (12.12)                                     | 0.929|
| Acute stroke (%)                               | 4   | 1 (2.86)                                   | 3 (9.09)                                      | 0.275|
| Hyperbilirubinemia (%)                         | 27  | 15 (42.86)                                 | 12 (36.36)                                    | 0.584|
| ALI (%)                                        | 10  | 9 (25.71)                                  | 1 (3.03)                                      | 0.008|
This study also has multiple limitations. (1) This is a single institution study and a retrospective study with a small sample size. (2) Considering the urgency of ECMO patients, peripheral artery-related diseases are often less considered in rescue, and the analysis of causes of vascular complications may be biased. (3) The placement of the ECMO tube and distal perfusion tube (DPC) is not standardized, but determined by the rescue physician.

5. Conclusion

Smoking history was an independent risk factor for ALI, while age, diabetes, cardiac arrest, first time of ECMO, and hyperbilirubinemia were associated risk factors for in-hospital mortality. Cardiac arrest and ALI were associated risk factors for mortality at 6 months after discharge. Although ALI is not significantly associated with VA-ECMO in-hospital mortality, it is a risk factor for mortality at 6 months after discharge, and medical personnel should therefore strive to reduce and avoid ALI.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Xiang Li and Guang Chen are the co-first authors.
Acknowledgments

The study was financially supported by grants from the Taizhou Municipal Bureau of Science and Technology (No. 1901KY09).

References

[1] B. Koons and J. Siebert, “Extracorporeal membrane oxygenation as a bridge to lung transplant: considerations for critical care nursing practice,” Critical Care Nurse, vol. 40, no. 3, pp. 49–57, 2020.

[2] I. Ratnani, D. Tuazon, A. Zainab, and F. Uddin, “The role and impact of extracorporeal membrane oxygenation in critical care,” Methodist DeBakey Cardiovascular Journal, vol. 14, no. 2, pp. 110–119, 2018.

[3] A. A. Grant, V. J. Hart, E. B. Lineen et al., “A weaning protocol for venovenous extracorporeal membrane oxygenation with a review of the literature,” Artificial Organs, vol. 42, no. 6, pp. 605–610, 2018.

[4] A. Xie, P. Lo, T. D. Yan, and P. Forrest, “Neurologic complications of extracorporeal membrane oxygenation: a review,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 31, no. 5, pp. 1836–1846, 2017.

[5] J. E. Millar, J. P. Fanning, C. I. McDonald, D. F. McAuley, and J. F. Fraser, “The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology,” Critical Care, vol. 20, no. 1, p. 387, 2016.

[6] X. Yang, S. Cai, Y. Luo et al., “Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study,” Critical Care Medicine, vol. 48, no. 9, pp. 1289–1295, 2020.

[7] R. E. Culbrett and L. T. Goodfellow, “Complications of prone positioning during extracorporeal membrane oxygenation for respiratory failure: a systematic review,” Respiratory Care, vol. 61, no. 2, pp. 249–254, 2016.

[8] S. Paolone, “Extracorporeal membrane oxygenation (ECMO) for lung injury in severe acute respiratory distress syndrome (ARDS): review of the literature,” Clinical Nursing Research, vol. 26, no. 6, pp. 747–762, 2017.

[9] T. Yuan, N. Yang, W. Bi et al., “Protective role of sulodexide on renal injury induced by limb ischemia-reperfusion,” Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 6629718, 9 pages, 2021.

[10] Y. Sanaitha, K. Bailey, P. Downey et al., “Trends in mortality and resource utilization for extracorporeal membrane oxygenation in the United States: 2008–2014,” Surgery, vol. 165, no. 2, pp. 381–388, 2019.

[11] M. Chung, Y. Zhao, J. B. Strom, C. Shen, and R. W. Yeh, “Extracorporeal membrane oxygenation use in cardiogenic shock,” Critical Care Medicine, vol. 47, no. 3, pp. e214–e221, 2019.

[12] A. Yuliat, M. Federman, L. M. Rao, L. Chen, M. S. Sim, and J. H. Matsumoto, “Prevalence of seizures and risk factors for mortality in a continuous cohort of pediatric extracorporeal membrane oxygenation patients,” Pediatric Critical Care Medicine, vol. 21, no. 11, pp. 949–958, 2020.

[13] L. C. Napp, C. Kühn, M. M. Hoepfer et al., “Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults,” Clinical Research in Cardiology, vol. 105, no. 4, pp. 283–296, 2016.

[14] B. T. Katzen, “Clinical diagnosis and prognosis of acute limb ischemia,” Reviews in Cardiovascular Medicine, vol. 3, no. 2, pp. S2–S6, 2002.

[15] K. Ramanathan, C. S. Tan, P. Rycus, and G. MacLaren, “Extracorporeal membrane oxygenation for adult community-acquired pneumonia,” Critical Care Medicine, vol. 45, no. 5, pp. 814–821, 2017.

[16] L. Munshi, A. Walkey, E. Goligher, T. Pham, E. M. Uleryk, and E. Fan, “Venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome: a systematic review and meta-analysis,” The Lancet Respiratory Medicine, vol. 7, no. 2, pp. 163–172, 2019.

[17] A. Zangrillo, G. Landoni, G. Biondi-Zoccai et al., “A meta-analysis of complications and mortality of extracorporeal membrane oxygenation,” Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, vol. 15, no. 3, pp. 172–178, 2013.

[18] A. Jacquot, X. Lepage, L. Merckle, N. Girend, and B. Levy, “Protocol for a multicentre randomised controlled trial evaluating the effects of moderate hypothermia versus normothermia on mortality in patients with refractory cardiogenic shock rescued by venoarterial extracorporeal membrane oxygenation (VA-ECMO) (HYPO-ECMO study),” BMJ Open, vol. 9, no. 10, Article ID e031697, 2019.

[19] L. Avalli, F. Sangalli, M. Migliari et al., “Early vascular complications after percutaneous cannulation for extracorporeal membrane oxygenation for cardiac assist,” Minerva Anestesiologica, vol. 82, no. 1, pp. 36–43, 2016.

[20] D. K. Bailly, R. W. Reeder, M. Winder et al., “Development of the pediatric extracorporeal membrane oxygenation prediction model for risk-adjusting mortality,” Pediatric Critical Care Medicine, vol. 20, no. 5, pp. 426–434, 2019.

[21] C. P. O’Halloran, K. G. Andren, J. Mecklosky et al., “Mortality and factors associated with hemorrhage during pediatric extracorporeal membrane oxygenation,” Pediatric Critical Care Medicine: A Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, vol. 21, no. 1, pp. 75–81, 2020.

[22] T. Bisdas, G. Beutel, G. Warnecke et al., “Vascular complications in patients undergoing femoral cannulation for extracorporeal membrane oxygenation support,” The Annals of Thoracic Surgery, vol. 92, no. 2, pp. 626–631, 2011.

[23] F. Aziz, C. E. Brehm, A. El-Banyosy, D. C. Han, R. G. Atnip, and A. B. Reed, “Arterial complications in patients undergoing extracorporeal membrane oxygenation via femoral cannulation,” Annals of Vascular Surgery, vol. 28, no. 1, pp. 178–183, 2014.

[24] S. D. Keene, R. M. Patel, B. K. Stansfield, J. Davis, C. D. Josephson, and A. M. Winkler, “Blood product transfusion and mortality in neonatal extracorporeal membrane oxygenation,” Transfusion, vol. 60, no. 2, pp. 262–268, 2020.

[25] P. J. Foley, R. J. Morris, E. Y. Woo et al., “Limb ischemia during femoral cannulation for cardiopulmonary support,” Journal of Vascular Surgery, vol. 52, no. 4, pp. 850–853, 2010.

[26] Y.-Y. Juo, M. Skancke, Y. Sanaitha, A. Mantha, J. C. Jimenez, and P. Benharash, “Efficacy of distal perfusion cannulae in preventing limb ischemia during extracorporeal membrane oxygenation: a systematic review and meta-analysis,” Artificial Organs, vol. 41, no. 11, pp. E263–E273, 2017.

[27] D. Zimpfer, B. Heinisch, M. Czerny et al., “Late vascular complications after extracorporeal membrane oxygenation support,” The Annals of Thoracic Surgery, vol. 81, no. 3, pp. 892–895, 2006.

[28] K. M. Lamb, P. J. DiMuzio, A. Johnson et al., “Arterial protocol including prophylactic distal perfusion catheter decreases limb ischemia complications in patients undergoing extracorporeal membrane oxygenation,” Journal of Vascular Surgery, vol. 65, no. 4, pp. 1074–1079, 2017.